Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.8% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 513,898 shares of the medical instruments supplier’s stock after selling 43,636 shares during the period. Envestnet Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $120,103,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. WR Wealth Planners LLC grew its holdings in Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the period. Ridgewood Investments LLC boosted its holdings in Becton, Dickinson and Company by 1.5% during the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after buying an additional 43 shares in the last quarter. Key Client Fiduciary Advisors LLC grew its position in Becton, Dickinson and Company by 2.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after buying an additional 43 shares during the period. Clear Creek Financial Management LLC increased its holdings in Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares in the last quarter. Finally, Edge Capital Group LLC increased its holdings in Becton, Dickinson and Company by 3.1% in the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock valued at $384,000 after buying an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BDX. Evercore ISI dropped their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $234.04 on Tuesday. The company has a fifty day simple moving average of $234.88 and a 200-day simple moving average of $235.60. The firm has a market capitalization of $67.64 billion, a price-to-earnings ratio of 51.55, a PEG ratio of 1.91 and a beta of 0.42. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter in the prior year, the company earned $2.96 EPS. Becton, Dickinson and Company’s revenue was up 2.3% compared to the same quarter last year. On average, equities analysts anticipate that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.